Redeye comments on Faron’s announcements of the phase I/II investigator-initiated trials BEXAR and BLAZE, evaluating bexmarilimab in metastatic soft-tissue sarcoma and NSCLC/melanoma. We view this expansion into high-unmet-need cancer indications as a strategically sound, low-risk/high-reward step that enables Faron to generate valuable proof-of-concept data with limited capital and operational burden.
LÄS MER
